[Clinical trial of the antibacterial combination sulfamoxole/trimethoprin (CN 3123). Fifth communication: Comparison of two double-blind studies with CN 3123 undertaken for demonstration of its efficacy (author's transl)].
Two double-blind trials which, independently, revealed the same conclusion that there is no significant difference between the therapeutic effect of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Neven, Supristol) and a reference preparation, were compared with each other in respect of rating the therapeutic result. The authors discuss the greater occurrence of Proteus pathogens at one trial centre, and its bearing on the rating of the therapeutic effect.
D001424:Bacterial Infections / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D006801:Humans; D008826:Microbial Sensitivity Tests; D013420:Sulfamethoxazole / Q000627:therapeutic use; D013423:Sulfamoxole / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use*
D004338:Drug Combinations; D014295:Trimethoprim; D013423:Sulfamoxole; D013420:Sulfamethoxazole
Klinische Prüfung der antibakteriellen Kombination Sulfamoxol/Trimethoprim (CN 3123). 5. Mitteilung: Vergleich der Ergebnisse von zwei zum Nachweis der Wirksamkeit von CN 3123 durchgeführten Doppelblindstudien